Ceftriaxone
* Please be kindly noted products are not for therapeutic use. We do not sell to patients.
| Category | Antibiotics |
| Catalog number | BBF-00750 |
| CAS | 73384-59-5 |
| Molecular Weight | 554.58 |
| Molecular Formula | C18H18N8O7S3 |
| Purity | >98% |
Online Inquiry
Description
It is produced by the strain of Semisynthetic third generation cephalosporin for injection. It has the third-generation cephalosporin commonness. It is characterized by a plasma elimination half-life of up to 7.1h, and one dose per day.
Specification
| Related CAS | 74578-69-1 (disodium salt) 104376-79-6 (disodium salt, hemiheptahydrate) |
| Synonyms | Biotrakson; Rocefin; Rocephalin; Rophex |
| Storage | −20 °C under inert atmosphere |
| IUPAC Name | (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(2-methyl-5,6-dioxo-1H-1,2,4-triazin-3-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid |
| Canonical SMILES | CN1C(=NC(=O)C(=O)N1)SCC2=C(N3C(C(C3=O)NC(=O)C(=NOC)C4=CSC(=N4)N)SC2)C(=O)O |
| InChI | InChI=1S/C18H18N8O7S3/c1-25-18(22-12(28)13(29)23-25)36-4-6-3-34-15-9(14(30)26(15)10(6)16(31)32)21-11(27)8(24-33-2)7-5-35-17(19)20-7/h5,9,15H,3-4H2,1-2H3,(H2,19,20)(H,21,27)(H,23,29)(H,31,32)/b24-8-/t9-,15-/m1/s1 |
| InChI Key | VAAUVRVFOQPIGI-SPQHTLEESA-N |
Properties
| Appearance | Off-white to Pale Yellow Solid |
| Melting Point | > 189 °C (dec.) |
| Density | 1.96±0.1 g/cm3 (Predicted) |
| Solubility | Slightly soluble in DMSO, Methanol |
| LogP | -1.7 |
Toxicity
| Carcinogenicity | No indication of carcinogenicity to humans (not listed by IARC). |
| Mechanism Of Toxicity | Ceftriaxone works by inhibiting the mucopeptide synthesis in the bacterial cell wall. The beta-lactam moiety of Ceftriaxone binds to carboxypeptidases, endopeptidases, and transpeptidases in the bacterial cytoplasmic membrane. These enzymes are involved in cell-wall synthesis and cell division. By binding to these enzymes, Ceftriaxone results in the formation of of defective cell walls and cell death. |
| Toxicity | LD50: >10 000 mg/kg (Oral, Rat). |
Reference Reading
1.Synthetic cathinone MDPV downregulates glutamate transporter subtype I (GLT-1) and produces rewarding and locomotor-activating effects that are reduced by a GLT-1 activator.
Gregg RA1, Hicks C1, Nayak SU1, Tallarida CS1, Nucero P1, Reitz AB2, Smith GR2, Rawls SM3. Neuropharmacology. 2016 Apr 13. pii: S0028-3908(16)30154-X. doi: 10.1016/j.neuropharm.2016.04.014. [Epub ahead of print]
Synthetic cathinones produce dysregulation of monoamine systems, but their effects on the glutamate system and the influence of glutamate on behavioral effects related to cathinone abuse are unknown. A principal regulator of glutamate homeostasis is glutamate transporter subtype 1 (GLT-1), an astrocytic protein that clears glutamate from the extracellular space and influences behavioral effects of established psychostimulants. We hypothesized that repeated administration of the synthetic cathinone, MDPV (3,4-methylenedioxypyrovalerone), would affect GLT-1 expression in the corticolimbic circuit, and that a GLT-1 activator (ceftriaxone, CTX) would reduce rewarding and locomotor-stimulant effects of MDPV in rats. GLT-1 protein expression in the nucleus accumbens (NAcc), but not prefrontal cortex (PFC), was decreased following withdrawal (2, 5 and 10 days) from repeated MDPV treatment, but not immediately after the last MDPV injection. CTX (200 mg/kg) pretreatment did not affect acute locomotor activation produced by MDPV (0.
2.Old but not forgotten: Antibiotic allergies in General Medicine (the AGM Study).
Trubiano JA1, Pai Mangalore R2, Baey YW3, Le D2, Graudins LV4, Charles PG2, Johnson DF2, Aung AK4. Med J Aust. 2016 Apr 18;204(7):273.
OBJECTIVES: To determine the nature, prevalence and description accuracy of recorded antibiotic allergy labels (AALs) in a cohort of general medical inpatients, and to assess the feasibility of an oral antibiotic re-challenge study.
3.Azithromycin-resistant Neisseria gonorrhoeae isolates in Guangzhou, China (2009-2013): coevolution with decreased susceptibilities to ceftriaxone and genetic characteristics.
Liang JY1,2, Cao WL1,2, Li XD1,2, Bi C1,2, Yang RD1,2, Liang YH1,2, Li P1,2, Ye XD1,2, Chen XX1,2, Zhang XB3,4. BMC Infect Dis. 2016 Apr 14;16(1):152. doi: 10.1186/s12879-016-1469-3.
BACKGROUND: The recent emergence of azithromycin-resistant (AZM-R) N. gonorrhoeae isolates that have coevolved decreased susceptibility to extended-spectrum cephalosporins has caused great concern. Here we investigated the prevalence of decreased susceptibility to ceftriaxone (CRO(D)) in AZM-R isolates and genetically characterized AZM-R isolates in Guangzhou, China from 2009 to 2013.
Spectrum
Predicted GC-MS Spectrum - GC-MS (Non-derivatized) - 70eV, Positive
Experimental Conditions
Ionization Mode: Positive
Ionization Energy: 70 eV
Chromatography Type: Gas Chromatography Column (GC)
Instrument Type: Single quadrupole, spectrum predicted by CFM-ID(EI)
Mass Resolution: 0.0001 Da
Molecular Formula: C18H18N8O7S3
Molecular Weight (Monoisotopic Mass): 554.0461 Da
Molecular Weight (Avergae Mass): 554.58 Da
Ionization Energy: 70 eV
Chromatography Type: Gas Chromatography Column (GC)
Instrument Type: Single quadrupole, spectrum predicted by CFM-ID(EI)
Mass Resolution: 0.0001 Da
Molecular Formula: C18H18N8O7S3
Molecular Weight (Monoisotopic Mass): 554.0461 Da
Molecular Weight (Avergae Mass): 554.58 Da
Predicted LC-MS/MS Spectrum - 10V, Positive
Experimental Conditions
Ionization Mode: Positive
Collision Energy: 10 eV
Instrument Type: QTOF (generic), spectrum predicted by CFM-ID
Mass Resolution: 0.0001 Da
Molecular Formula: C18H18N8O7S3
Molecular Weight (Monoisotopic Mass): 554.0461 Da
Molecular Weight (Avergae Mass): 554.58 Da
Collision Energy: 10 eV
Instrument Type: QTOF (generic), spectrum predicted by CFM-ID
Mass Resolution: 0.0001 Da
Molecular Formula: C18H18N8O7S3
Molecular Weight (Monoisotopic Mass): 554.0461 Da
Molecular Weight (Avergae Mass): 554.58 Da
1H NMR Spectrum
Experimental Conditions
Solvent: D2O
Nucleus: 1H
Frequency: 100
Nucleus: 1H
Frequency: 100
Recommended Products
| BBF-05862 | Epirubicin | Inquiry |
| BBF-00764 | Cerebroside C | Inquiry |
| BBF-03754 | CASTANOSPERMINE | Inquiry |
| BBF-00677 | 3-Amino-3-deoxy-D-glucose | Inquiry |
| BBF-01826 | Deoxymannojirimycin | Inquiry |
| BBF-02614 | Nystatin | Inquiry |
Bio Calculators
* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2
* Total Molecular Weight:
g/mol
Tip: Chemical formula is case sensitive. C22H30N4O √ c22h30n40 ╳
